Group 1 - China Biopharmaceutical (1177.HK) saw a rise of over 3% after announcing a successful licensing agreement with Merck for its PD-1/VEGF dual antibody, expecting a $300 million milestone payment soon [1] - CSPC Pharmaceutical Group (1093.HK) increased by over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development of its GLP-1 receptor agonist SYH2086 [1] - Youzan (8083.HK) surged over 7% as it projected a revenue of approximately 709 to 719 million RMB for the first half of the year, a year-on-year increase of about 3.3% to 4.8%, and a net profit of 68 to 74 million RMB, marking a turnaround from a loss last year [1] Group 2 - Xingsheng International (6058.HK) rose nearly 18% after the bank announced its commitment to embrace technological transformation and explore stablecoins and AI initiatives [2] - New Oriental Education (9901.HK) fell nearly 4% after reporting a 9.4% year-on-year increase in net revenue to $1.243 billion for the fourth quarter of fiscal year 2025, but a 73.7% drop in net profit [2] - Kingdee International (0268.HK) saw a rise of over 7% as it announced a board meeting to review its interim results and potential dividend distribution [2] Group 3 - Macau gaming stocks rose, with MGM China (2282.HK) up over 4% after Macquarie raised its forecast for Macau's total gaming revenue for 2025 by 5% to 235.7 billion RMB, indicating a year-on-year growth of 4% [3] - Gold stocks in Hong Kong continued to decline, with Tongguan Gold (0340.HK) dropping over 9% for six consecutive days, as spot gold prices fell below $3,270 per ounce [4] - Kangfang Biopharma (9926.HK) rose nearly 5% after announcing the completion of the first patient dosing in a pivotal clinical trial for its PD-1/VEGF dual-specific antibody [4] Group 4 - Weishi Jiajie (0856.HK) increased by over 3% as a report indicated that its Southeast Asia business is expected to see a significant revenue increase of 74% in 2024, with net profit contributing about 51% [5] Group 5 - Meta (META.US) exceeded revenue expectations and provided strong guidance for the current quarter, leading to an after-hours increase of over 11% [6] - Microsoft (MSFT.US) reported an 18% year-on-year growth in revenue, driven by its cloud business, with Azure revenue up 34% for the full year, resulting in an after-hours increase of over 8% [6] - Wingstop (WING.US) surged by 26.85% after reporting adjusted earnings per share of $1.00 for the second quarter, exceeding analyst expectations [6] Group 6 - Several biopharmaceutical stocks surged, with Replimune (REPL.US) up 101.33% following news of regulatory changes at the FDA that may ease pressure on gene therapy and vaccine companies [7] - Marvell Technology (MRVL.US) rose 7.07% after announcing a partnership with Rebellions to provide AI systems for regional projects in Asia-Pacific and the Middle East [7] - Palo Alto Networks (PANW.US) fell 5.58% after agreeing to acquire CyberArk Software for approximately $25 billion [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, affecting investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo and the implications for Hims subscribers' access to the weight-loss drug Wegovy [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Key Takeaways Hims & Hers Health, Inc. (HIMS) is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the last reported quarter, the company's earnings per share (EPS) of 20 cents topped the Zacks Consensus Estimate by 66.7%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on two occasions, missed once and broke even in the other, delivering an earnings surprise of 19.6%, on average. Let's check out the factors that have shaped HIMS' p ...

智通财经APP获悉，周三，Hims & Hers Health(HIMS.US)涨超7%，月内累涨30%，报64.51美元。消息 面上，该公司将于美东时间08月04日盘后发布财报，机构预期2025Q2实现营收5.52亿美元，同比增加 74.89%;预期每股收益0.165美元，同比增加174.5%。 ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk and the sale of compounded semaglutide [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until August 25, 2025, to request to lead the case [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations and Impact - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming compliance with FDA regulations regarding the sale of compounded semaglutide [4]. - Following the termination of the partnership by Novo Nordisk on June 23, 2025, due to deceptive practices, Hims & Hers stock price fell by $22.24 per share, a decline of over 34% [5].

NEW YORK, July 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ps ...

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Hims & Hers Health, Inc. and Sarepta Therapeutics, Inc. due to alleged misleading statements and undisclosed material facts regarding their business operations and prospects [1][4]. Hims & Hers Health, Inc. (NYSE: HIMS) - Class period is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion of illegitimate versions of Wegovy, risking patient safety and jeopardizing collaboration with Novo Nordisk [2][3]. - Defendants are accused of making false statements about the partnership with Novo, which was supposed to ensure access to Wegovy for Hims subscribers, and misrepresenting the offerings of compounded semaglutide products [3]. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Class period is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [4]. - The complaint alleges that Sarepta misled investors about the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - Specific allegations include failure to disclose significant safety risks associated with ELEVIDYS, misleading statements about trial protocols, and the potential for regulatory scrutiny due to adverse events [4]. - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock price fell by $27.81 per share, or 27.44% [5]. - Subsequent disclosures of additional patient deaths led to further declines in stock price, including a drop of $15.24 per share, or 42.12%, on June 15, 2025 [6].

Company Performance - Hims & Hers Health, Inc. (HIMS) closed at $58.68, marking a +1.79% move from the prior day, outperforming the S&P 500's daily gain of 0.02% [1] - The stock has risen by 16.68% in the past month, leading the Medical sector's gain of 1.92% and the S&P 500's gain of 4.93% [1] Upcoming Earnings - The company is scheduled to release its earnings on August 4, 2025, with projected earnings of $0.18 per share, representing year-over-year growth of 200% [2] - The consensus estimate for revenue is $551.84 million, reflecting a 74.83% rise from the equivalent quarter last year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.75 per share and revenue of $2.35 billion, signifying shifts of +177.78% and +58.88% respectively from the last year [3] Analyst Estimates and Confidence - Recent revisions in analyst estimates reflect the latest near-term business trends, with positive revisions indicating analysts' confidence in the business performance and profit potential [3][4] Zacks Rank and Performance - Hims & Hers Health, Inc. currently possesses a Zacks Rank of 1 (Strong Buy), with the Zacks Rank system showing an impressive track record of outperformance [5] - Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.27% higher [5] Valuation Metrics - The company has a Forward P/E ratio of 77.22, which is a premium compared to the average Forward P/E of 27.59 for its industry [6] - HIMS has a PEG ratio of 2.13, compared to the average PEG ratio for the Medical Info Systems industry, which stood at 3.15 [7] Industry Overview - The Medical Info Systems industry is part of the Medical sector and currently holds a Zacks Industry Rank of 74, placing it in the top 30% of all 250+ industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Viewpoint - Berger Montague is investigating potential securities fraud claims against Hims & Hers Health Inc. for making false or misleading statements to investors during the Class Period from April 29, 2025, to June 22, 2025 [1][2] Securities Fraud Investigation Details - On June 23, 2025, Hims & Hers shares fell over 34% after Novo Nordisk terminated its partnership due to unauthorized marketing and sale of compounded semaglutide drugs [2] - A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws [2] Deadline to Act - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit [3] - Lead plaintiffs will help direct the case and advocate on behalf of other harmed investors [3]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the weight loss drug Wegovy®, resulting in a significant drop in its stock price after the termination of its partnership with Novo Nordisk [1][4][5]. Group 1: Company Overview - Hims & Hers Health is a telehealth company that offers prescription and over-the-counter medications, as well as personal care products [3]. Group 2: Legal Allegations - The class action lawsuit claims that during the Class Period, Hims & Hers made false and misleading statements and failed to disclose material facts, including engaging in deceptive promotion of illegitimate versions of Wegovy® [4]. - The lawsuit also alleges that there was a significant risk of Novo Nordisk terminating its collaboration with Hims & Hers due to these deceptive practices [4]. Group 3: Impact of Events - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing concerns over patient safety due to the deceptive promotion of knockoff versions of Wegovy® [5]. - Following the announcement of the partnership termination, Hims & Hers shares fell more than 34% [5].